International Pharmaceutical Aerosol Consortium
Acronym: IPAC
General Information
Identification Code: 602537137644-70
Website: [object Object]
Entity Form: Trade Association (non-profit)
Registration Category: Trade and business associations
Registration Date: 3/16/2020
Last Update: 3/4/2024
EP Accredited Number: 0
Mission & Interests
Goals: The International Pharmaceutical Aerosol Consortium (IPAC) was formed in 1989 in response to the mandates of the Montreal Protocol on Substances that Deplete the Ozone Layer and fully supported a timely and effective transition away from chlorofluorocarbons (CFCs) used in pressurised metered dose inhalers (pMDIs) under the Montreal Protocol that balanced patient health and environmental concerns. IPAC’s mission is to ensure that environmental policies relevant to inhaled therapies are patient-centric and appropriately balance both patient care and sustainability objectives. IPAC members research and develop CFC-free products – HFC pMDIs, dry powder inhalers (DPIs) and soft mist inhalers (SMIs). In light of this history and deep expertise, IPAC is uniquely positioned to serve as a resource in efforts related to the intersection of environmental policies and inhaled therapies. IPAC’s members are AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GSK, Kindeva, Organon & Teva.
Interests Represented: Promotes their own interests or the collective interests of their members
Interests:
- Climate action
- Environment
- Public health
Levels of Interest:
- global
- sub-national
- european
- national
Activities
Main EU Legislative Proposals: IPAC's focus is on environmental/climate change policies related to fluorinated gases and, in particular, hydrofluorocarbons (HFCs) 134a and 227ea which are used as aerosol propellants in inhaled therapies. IPAC is engaging with the Commission and other stakeholders on the review of the European F-Gases Regulation: Regulation (EU) No 517/2014 of the European Parliament and of the Council of 16 April 2014 on fluorinated greenhouse gases.
Communication Activities: IPAC's activities in 2023 are summarized below.
IPAC has engaged with the European Commission, staff/members of Parliament, and Council on issues relevant to the use of HFCs as medical propellants. We submitted a joint stakeholder letter to many senior EU policymakers in January 2023. A copy of the letter is posted on IPAC's website: www.ipacinhaler.org.
IPAC also responded to a public questionnaire on ECHA Reach/PFAS issues in May and September. A copy is available on www.ipacinhaler.org.
EU Supported Forums and Platforms: Consultation Forum according to Art. 23 of Regulation (EU) No 517/2014 on fluorinated greenhouse gases#X03338#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=3338 #MEMBER #C#Civil society#Industry
Inter-institutional or Unofficial Groupings: Climate change, biodiversity and sustainable development
Head Office
Address: 1500 K Street, NWSuite 1100
Post Code: 20005
City: Washington
Country: UNITED STATES
Phone: [object Object]
EU Office
Address: 1500 K Street, NWSuite 1100
Post Code: 20005
City: Washington
Country: UNITED STATES
Phone: [object Object]
Financial Data
New Organisation: false
Closed Year: [object Object]
Current Year: [object Object]
Membership Information
Members10 Percent: 0
Members25 Percent: 2
Members50 Percent: 0
Members75 Percent: 0
Members: 2
Members F T E: 0.5
Structure
Structure Type: Structure
Is Member Of: IPAC’s members are AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GSK, Kindeva, Organon, and Teva. See www.ipacinhaler.org.
Organisation Members: IPAC is an associate member of the Alliance for Responsible Atmospheric Policy, please see: http://alliancepolicy.org/.